This site is intended for healthcare professionals

SGLT inhibitors for treating type 1 diabetes: NICE technology appraisals TA597 and TA622

Posted 12 June 2020

Dr David Millar-Jones

Dr David Millar-Jones summarises the key points for primary care relating to use of sodium–glucose cotransporter inhibitors in people with type 1 diabetes.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.